Search Results

Nanite, Inc. and SalioGen Therapeutics announced a research collaboration that will utilize Nanite’s SAYER™ delivery platform to develop a lung-targeting polymer nanoparticle designed to integrate the cystic fibrosis transmembrane conductance regulator gene directly into lung cells using SalioGen’s novel Gene Coding™ technology.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.

Abdera Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy.

Aerami Therapeutics announced the presentation of new lung deposition modeling data for AER-901 at the American Thoracic Society 2024 International Conference being held May 17-22, 2024, in San Diego, California.

Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. (“Lung Tx”).

The small cell lung cancer therapeutics market size was valued at 5.75 billion in 2023 and is anticipated to reach around 16.33 billion by 2032, expanding at a CAGR of 12.3% from 2023 to 2032.

OSE Immunotherapeutics joins key opinion leaders Dr Stephen Liu, associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center and Prof Benjamin Besse, medical oncologist and director of clinical research at the Gustave Roussy Institute, to discuss the current unmet medical needs in lung cancer therapeutics and the development landscape of OSE Immunotherapeutics therapeutic cancer vaccine, Tedopi®.